drugset / Trial / NCT03287271
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.
Timeline
- Start
- 2018-02-06
- Primary completion
- 2025-04
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Defactinib | Small molecule | 200 mg | Oral |
| Subject | Defactinib | Small molecule | 400 mg | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |